Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma

NCT03709953 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Lung Carcinoma

Interventions

DRUG: Apatinib

Sponsor

Guangzhou Institute of Respiratory Disease

Collaborators

[object Object]